Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

165 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gaps in evidence in the treatment of prevalent patients with pulmonary arterial hypertension at intermediate risk: An expert consensus.
Manzi G, Benza RL, Argiento P, Casu G, Corda M, Correale M, D'Alto M, Galgano G, Garascia A, Ghio S, Gomberg-Maitland M, Mulé M, Paciocco G, Papa S, Prati D, Preston IR, Raineri C, Romeo E, Scelsi L, Stolfo D, Vitulo P, White RJ, Badagliacca R, Vizza CD. Manzi G, et al. Among authors: gomberg maitland m. Vascul Pharmacol. 2024 Dec;157:107432. doi: 10.1016/j.vph.2024.107432. Epub 2024 Sep 10. Vascul Pharmacol. 2024. PMID: 39265796 Review.
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group. Simonneau G, et al. Ann Intern Med. 2008 Oct 21;149(8):521-30. doi: 10.7326/0003-4819-149-8-200810210-00004. Ann Intern Med. 2008. PMID: 18936500 Clinical Trial.
Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani HA, Hoeper MM, Lang IM, Preiss R, Rubin LJ, Di Scala L, Tapson V, Adzerikho I, Liu J, Moiseeva O, Zeng X, Simonneau G, McLaughlin VV; GRIPHON Investigators. Sitbon O, et al. N Engl J Med. 2015 Dec 24;373(26):2522-33. doi: 10.1056/NEJMoa1503184. N Engl J Med. 2015. PMID: 26699168 Free article. Clinical Trial.
Efficacy and safety of sotatercept across ranges of cardiac index in patients with pulmonary arterial hypertension: A pooled analysis of PULSAR and STELLAR.
Gomberg-Maitland M, Badesch DB, Gibbs JSR, Grünig E, Hoeper MM, Humbert M, Kopeć G, McLaughlin VV, Meyer G, Olsson KM, Preston IR, Rosenkranz S, Souza R, Waxman AB, Perchenet L, Strait J, Xing A, Johnson-Levonas AO, Cornell AG, de Oliveira Pena J, Ardeschir Ghofrani H. Gomberg-Maitland M, et al. J Heart Lung Transplant. 2024 Dec 5:S1053-2498(24)02009-6. doi: 10.1016/j.healun.2024.11.037. Online ahead of print. J Heart Lung Transplant. 2024. PMID: 39645016
Mechanisms and treatment of pulmonary arterial hypertension.
Ghofrani HA, Gomberg-Maitland M, Zhao L, Grimminger F. Ghofrani HA, et al. Among authors: gomberg maitland m. Nat Rev Cardiol. 2024 Aug 7. doi: 10.1038/s41569-024-01064-4. Online ahead of print. Nat Rev Cardiol. 2024. PMID: 39112561 Review.
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani HA, Jansa P, Jing ZC, Le Brun FO, Mehta S, Mittelholzer CM, Perchenet L, Sastry BK, Sitbon O, Souza R, Torbicki A, Zeng X, Rubin LJ, Simonneau G; SERAPHIN Investigators. Pulido T, et al. N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917. N Engl J Med. 2013. PMID: 23984728 Free article. Clinical Trial.
165 results